The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Hepatokines: unlocking the multi-organ network in metabolic diseases
Open accessAbstract
In the face of urbanisation, surplus energy intake, sedentary habits and obesity, type 2 diabetes has developed into a major health concern worldwide. Commonly overlooked in contemporary obesity research, the liver is emerging as a central regulator of whole body energy homeostasis. Liver-derived proteins known as hepatokines are now considered attractive targets for the development of novel type 2 diabetes treatments. This commentary presents examples of three leading hepatokines: fetuin-A, the first to be described and correlated with increased inflammation and insulin resistance; angiopoietin-like protein (ANGPTL)8/betatrophin, initially proposed for its action on beta cell proliferation, although this effect has recently been brought into question; and fibroblast growth factor 21 (FGF21), an insulin-sensitising hormone that is an appealing drug target because of its beneficial metabolic actions. Novel discoveries in hepatokine research may lead to promising biomarkers and treatments for metabolic disorders and type 2 diabetes. This is one of a series of commentaries under the banner '50 years forward', giving personal opinions on future perspectives in diabetes, to celebrate the 50th anniversary of Diabetologia (1965-2015).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NAFLD is the most common chronic liver disease worldwide and a risk factor for type 2 diabetes, obesity, and cardiovascular disease (CVD) [8,12,22].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation
Yi, P., Park, J.-S., & Melton, D. A. (2013) · Cell · doi:10.1016/j.cell.2013.04.008 · Cited by 449
RetractedBadman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Michael, M. D., Kulkarni, R. N., Postic, C., Previs, S. F., Shulman, G. I., Magnuson, M. A., & Kahn, C. R. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00015-8 · Cited by 1,296
Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance
Pal, D., Dasgupta, S., Kundu, R., Maitra, S., Das, G., Mukhopadhyay, S., Ray, S., Majumdar, S. S., & Bhattacharya, S. (2012) · Nature Medicine · doi:10.1038/nm.2851 · Cited by 922 · cited 1×
“Identified as an adaptor protein for saturated fatty acidmediated activation of Toll-like receptor 4, this fetuin-A–fatty acid synergy may induce inflammatory signalling and insulin resistance—two important driving forces behind type 2 diabetes [6].”
BackgroundThe effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885
The internal secretion of the pancreas
Banting, F., & BEST, C. H. (1922) · Journal of Laboratory and Clinical Medicine · doi:10.5555/uri:pii:s0022214322903841 · Cited by 829
Effects of parabiosis of obese with diabetes and normal mice.
Coleman, D. L. (1973) · Diabetologia · doi:10.1007/bf01221857 · Cited by 729
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela–Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez–Chantar, M. L., & Maratos–Flier, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.054 · Cited by 607
The role of hepatokines in metabolism
Stefan, N., & Häring, H.-U. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.258 · Cited by 500
Fructose ingestion acutely stimulates circulating FGF21 levels in humans
Dushay, J. R., Toschi, E., Mitten, E. K., Fisher, F. M., Herman, M. A., & Maratos-Flier, E. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.09.008 · Cited by 233
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–111 of 111
(2023) · Wiley eBooks · doi:10.1002/9781394236329.refs
Exploring the link between fructose intake and Non-Alcoholic Fatty Liver Disease (NAFLD)
Arslanbulut, G., & Çiftçi, S. (2023) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2023.10.004
Chen, L., Wang, R., Lv, X., Kan, M., Zhang, H., Qiu, W., Chen, S., Zhao, J., Wen, X., Meng, X., et al. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116371
Alenazi, M. A., Sabico, S., Alnaami, A. M., Wani, K., Hussain, S. D., & Al‐Daghri, N. M. (2025) · BMC Pediatrics · doi:10.1186/s12887-025-05833-z
He, Y., Yang, T., Qiu, R., Liu, B., Wang, S., Wang, J., & Zheng, F. (2025) · medRxiv · doi:10.1101/2025.10.15.25338095
He, Y., Yang, T., Qiu, R., Liu, B., Wang, S., Wang, J., & Zheng, F. (2025) · eLife · doi:10.7554/elife.109425
He, Y., Yang, T., Qiu, R., Liu, B., Wang, S., Wang, J., & Zheng, F. (2025) · eLife · doi:10.7554/elife.109425.1
Hypothalamus-liver talks: whispers in the language of metabolism
Ferreira, V., Fernández-González, I., Vattathara, J. J., Rodríguez-Díaz, A., Fernández-Sanmartín, P., & Diéguez, C. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10031-y
Rôle de LECT2 dans les maladies stéatosiques non alcooliques du foie
Pham, S. (2020) · theses.fr (ABES) · doi:10.70675/3693bfe6z9d91z4045za9a9zc37497dc9c1b
Metadata
- Authors
- Iroz, A., Couty, J.-P., & Postic, C.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Postic, Catherine
- Venue
- Diabetologia
- Published
- 2015-06-02
- Volume
- 58
- Issue
- 8
- Pages
- 1699-1703
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W593049947
- Cited by
- 111
- References
- 23
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 6 · 2023: 12 · 2022: 9 · 2021: 6 · 2020: 13 · 2019: 13 · 2018: 8 · 2017: 15 · 2016: 13 · 2015: 3
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale (U1016)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- hepatokines, fetuin-A, FGF21, type 2 diabetes, obesity, insulin resistance, energy homeostasis, liver, therapeutic target, biomarkers
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 8, Animals, Diabetes Mellitus, Type 2, Fibroblast Growth Factors, Humans, Insulin Resistance, Liver, Metabolic Diseases, Obesity, Peptide Hormones, alpha-2-HS-Glycoprotein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
